Budimir Ivan, Tomasović-Lončarić Čedna, Kralik Kristina, Čonkaš Josipa, Eljuga Domagoj, Žic Rado, Gorjanc Božo, Tucaković Hrvoje, Caktaš Doroteja, Jaman Josip, Lisek Valentino, Vlajčić Zlatko, Martić Krešimir, Ozretić Petar
Department of Plastic, Reconstructive and Aesthetic Surgery, Dubrava University Hospital, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
Life (Basel). 2022 Oct 7;12(10):1559. doi: 10.3390/life12101559.
Breast cancers (BC) are usually classified into four molecular subtypes according to the expression of estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors and proliferation marker Ki-67. Despite available anti-hormonal therapies and due to the inherent propensity of some subtypes to develop metastasis, there is a permanent need to discover new prognostic and predictive biomarkers, as well as therapeutic targets for BC. In this study, we used immunohistochemical staining to determine the expression of androgen receptor (AR) and sonic hedgehog protein (SHH), the main ligand of the Hedgehog-GLI (HH-GLI) signaling pathway, in 185 archival primary BC tissue samples and correlated it with clinicopathological characteristics, molecular subtypes, receptors statuses, and survival in a cohort of Croatian BC patients. Results showed that higher SHH and AR expressions were associated with positive receptor status, but increased SHH expression had a negative impact on survival in receptor-negative BCs. On the contrary, higher AR expression was mostly protective. However, multivariate analysis showed that only higher AR expression could be considered as an independent prognostic biomarker for poorer overall survival in triple-negative breast cancer patients (TNBC) (HR 10.9, 95% CI 1.43-83.67; = 0.021), what could be Croatian population-related. SHH could be a potential target for treating TNBCs and HER2-enriched BCs, in cases where HH-GLI signaling is canonical (SHH-dependent).
乳腺癌(BC)通常根据雌激素(ER)、孕激素(PR)、人表皮生长因子2(HER2)受体的表达以及增殖标志物Ki-67分为四种分子亚型。尽管有可用的抗激素疗法,且由于某些亚型具有发生转移的内在倾向,但一直需要发现新的预后和预测生物标志物以及BC的治疗靶点。在本研究中,我们使用免疫组织化学染色来确定雄激素受体(AR)和刺猬信号通路主要配体音猬因子(SHH)在185例存档的原发性BC组织样本中的表达,并将其与克罗地亚BC患者队列中的临床病理特征、分子亚型、受体状态和生存率相关联。结果表明,较高的SHH和AR表达与受体阳性状态相关,但SHH表达增加对受体阴性BC的生存有负面影响。相反,较高的AR表达大多具有保护作用。然而,多变量分析表明,只有较高的AR表达可被视为三阴性乳腺癌患者(TNBC)总体生存率较差的独立预后生物标志物(HR 10.9,95% CI 1.43 - 83.67;P = 0.021),这可能与克罗地亚人群有关。在刺猬信号通路经典(依赖SHH)的情况下,SHH可能是治疗TNBC和HER2富集型BC的潜在靶点。